['Financial', 'Condition', 'Results', 'Operations', 'included', 'elsewhere', 'Annual', 'Report', 'These', 'historical', 'results', 'necessarily', 'indicative', 'results', 'may', 'expected', 'future', 'periods', 'Year', 'Ended', 'December', '31', '2017(1', '2016(2', '2015(3', '2014(4', '2013(5', 'thousands', 'except', 'per', 'share', 'amounts', 'Statements', 'Operations', 'Data', 'Revenue', '31,176', '15,353', '36,250', '30,659', '20,915', 'Net', 'loss', '183,769', '279,966', '156,937', '82,947', '51,983', 'Basic', 'diluted', 'net', 'loss', 'per', 'share', '0.63', '1.03', '0.60', '0.37', '0.31', 'Weighted', 'average', 'shares', 'used', 'computing', 'basic', 'diluted', 'net', 'loss', 'per', 'share', '292,669', '270,802', '262,248', '225,848', '169,658', 'As', 'December', '31', '2017(1', '2016(2', '2015(3', '2014(4', '2013(5', 'thousands', 'Balance', 'Sheet', 'Data', 'Cash', 'cash', 'equivalents', 'marketable', 'securities', '157,303', '235,479', '230,656', '168,056', '133,068', 'Total', 'current', 'assets', '203,311', '287,830', '287,257', '188,158', '145,001', 'Working', 'capital(6', '129,636', '221,424', '210,763', '154,042', '126,879', 'Total', 'assets', '302,493', '394,301', '386,038', '276,002', '235,125', 'Long-term', 'debt', 'less', 'current', 'portion(7', '317,763', '316,339', '37', '503', '1,199', 'Accumulated', 'deficit', '1,114,359', '929,996', '650,030', '493,093', '410,146', 'Total', 'stockholders', 'deficit', 'equity', '101,732', '5,546', '292,669', '229,618', '203,234', '1)In', '2017', 'sales', '50,889,910', 'shares', 'common', 'stock', 'resulting', 'net', 'proceeds', 'approximately', '63', 'million', '2)In', '2016', 'issued', '325', 'million', 'aggregate', 'principal', 'amount', 'convertible', 'senior', 'unsecured', 'notes', 'resulting', 'net', 'proceeds', 'approximately', '315', 'million', '3)In', '2015', 'sales', '29,163,620', 'shares', 'common', 'stock', 'resulting', 'net', 'proceeds', 'approximately', '204', 'million', '4)In', '2014', 'sales', '28,750,000', 'shares', 'common', 'stock', 'resulting', 'net', 'proceeds', 'approximately', '108', 'million', '5)In', '2013', 'completed', 'acquisition', 'Novavax', 'AB', 'sales', '44,452,343', 'shares', 'common', 'stock', 'resulting', 'net', 'proceeds', 'approximately', '129', 'million', '6)Working', 'capital', 'computed', 'excess', 'current', 'assets', 'current', 'liabilities', '7)Includes', 'non-current', 'portion', 'capital', 'leases', '37', 'Item', '7.MANAGEMENT', 'S', 'DISCUSSION', 'AND', 'ANALYSIS', 'OF', 'FINANCIAL', 'CONDITION', 'AND', 'RESULTS', 'OF', 'OPERATIONS', 'Any', 'statements', 'discussion', 'elsewhere', 'Annual', 'Report', 'expectations', 'beliefs', 'plans', 'objectives', 'assumptions', 'future', 'events', 'performance', 'Novavax', 'Inc', 'Novavax', 'together', 'wholly', 'owned', 'subsidiary', 'Novavax', 'AB', 'Company', 'us', 'historical', 'facts', 'forward-looking', 'statements', 'Such', 'forward-looking', 'statements', 'include', 'without', 'limitation', 'statements', 'respect', 'capabilities', 'goals', 'expectations', 'regarding', 'future', 'revenue', 'expense', 'levels', 'capital', 'raising', 'activities', 'including', 'possible', 'proceeds', 'December', '2017', 'Sales', 'Agreement', 'potential', 'market', 'sizes', 'demand', 'product', 'candidates', 'efficacy', 'safety', 'intended', 'utilization', 'product', 'candidates', 'development', 'clinical-stage', 'product', 'candidates', 'recombinant', 'vaccine', 'adjuvant', 'technologies', 'development', 'preclinical', 'product', 'candidates', 'conduct', 'timing', 'potential', 'results', 'clinical', 'trials', 'preclinical', 'studies', 'plans', 'potential', 'timing', 'regulatory', 'filings', 'expected', 'timing', 'content', 'regulatory', 'actions', 'reimbursement', 'Department', 'Health', 'Human', 'Services', 'Biomedical', 'Advanced', 'Research', 'Development', 'Authority', 'HHS', 'BARDA', 'payments', 'license', 'Wyeth', 'Holdings', 'LLC', 'subsidiary', 'Pfizer', 'Inc', 'Wyeth', 'payments', 'Bill', 'Melinda', 'Gates', 'Foundation', 'BMGF', 'available', 'cash', 'resources', 'availability', 'financing', 'generally', 'plans', 'regarding', 'partnering', 'activities', 'business', 'development', 'initiatives', 'adoption', 'stock', 'incentive', 'plans', 'amendments', 'thereto', 'effectiveness', 'expected', 'costs', 'savings', 'timing', 'costs', 'savings', 'associated', 'implementation', 'restructuring', 'efforts', 'matters', 'referenced', 'herein', 'You', 'generally', 'identify', 'forward-looking', 'statements', 'use', 'words', 'phrases', 'believe', 'may', 'could', 'would', 'possible', 'estimate', 'continue', 'ongoing', 'consider', 'anticipate', 'intend', 'seek', 'plan', 'project', 'expect', 'would', 'assume', 'negative', 'terms', 'comparable', 'terminology', 'although', 'forward-looking', 'statements', 'contain', 'words', 'Forward-looking', 'statements', 'involved', 'estimates', 'assumptions', 'uncertainties', 'could', 'cause', 'actual', 'results', 'differ', 'materially', 'expressed', 'implied', 'statements', 'Any', 'forward-looking', 'statements', 'Annual', 'Report', 'may', 'turn', 'inaccurate', 'materially', 'different', 'actual', 'results', 'Because', 'risk', 'factors', 'discussed', 'Annual', 'Report', 'risk', 'factors', 'aware', 'could', 'cause', 'actual', 'results', 'outcomes', 'differ', 'materially', 'expressed', 'implied', 'forward-looking', 'statements', 'made', 'behalf', 'us', 'place', 'undue', 'reliance', 'forward-looking', 'statements', 'These', 'statements', 'subject', 'risks', 'uncertainties', 'known', 'unknown', 'could', 'cause', 'actual', 'results', 'developments', 'differ', 'materially', 'expressed', 'implied', 'statements', 'We', 'included', 'important', 'factors', 'cautionary', 'statements', 'included', 'Annual', 'Report', 'particularly', 'identified', 'Part', 'I', 'Item', '1A', 'Risk', 'Factors', 'Annual', 'Report', 'could', 'cause', 'actual', 'results', 'events', 'differ', 'materially', 'forward-looking', 'statements', 'These', 'risks', 'may', 'also', 'detailed', 'modified', 'updated', 'reports', 'documents', 'filed', 'Securities', 'Exchange', 'Commission', 'SEC', 'time', 'time', 'You', 'encouraged', 'read', 'filings', 'made', 'We', 'cannot', 'guarantee', 'future', 'results', 'events', 'level', 'activity', 'performance', 'achievement', 'Further', 'forward-looking', 'statement', 'speaks', 'date', 'made', 'undertake', 'obligation', 'update', 'revise', 'forward-looking', 'statements', 'whether', 'result', 'new', 'information', 'future', 'events', 'otherwise', 'unless', 'required', 'law', 'New', 'factors', 'emerge', 'time', 'time', 'possible', 'us', 'predict', 'factors', 'arise', 'In', 'addition', 'cannot', 'assess', 'impact', 'factor', 'business', 'extent', 'factor', 'combination', 'factors', 'may', 'cause', 'actual', 'results', 'differ', 'materially', 'contained', 'forward-looking', 'statements', '38', 'Overview', 'We', 'clinical-stage', 'biotechnology', 'company', 'focused', 'discovery', 'development', 'commercialization', 'recombinant', 'nanoparticle', 'vaccines', 'adjuvants', 'Using', 'innovative', 'proprietary', 'recombinant', 'nanoparticle', 'vaccine', 'technology', 'produce', 'vaccine', 'candidates', 'efficiently', 'effectively', 'respond', 'known', 'emerging', 'disease', 'threats', 'Our', 'vaccine', 'candidates', 'genetically', 'engineered', 'three-dimensional', 'nanostructures', 'incorporate', 'recombinant', 'proteins', 'critical', 'disease', 'pathogenesis', 'may', 'elicit', 'differentiated', 'immune', 'responses', 'may', 'efficacious', 'naturally', 'occurring', 'immunity', 'traditional', 'vaccine', 'Our', 'product', 'pipeline', 'targets', 'variety', 'infectious', 'diseases', 'clinical', 'vaccine', 'candidates', 'respiratory', 'syncytial', 'virus', 'RSV', 'influenza', 'Ebola', 'virus', 'EBOV', 'preclinical', 'programs', 'infectious', 'disease', 'vaccine', 'candidates', 'We', 'also', 'developing', 'immune', 'stimulating', 'saponin-based', 'adjuvants', 'wholly', 'owned', 'Swedish', 'subsidiary', 'Novavax', 'AB', 'Our', 'lead', 'adjuvant', 'Matrix-M', 'shown', 'enhance', 'immune', 'responses', 'well-tolerated', 'multiple', 'clinical', 'trials', 'conducted', 'Product', 'Pipeline', 'Our', 'product', 'pipeline', 'includes', 'vaccine', 'candidates', 'engineered', 'elicit', 'differentiated', 'immune', 'responses', 'potential', 'provide', 'increased', 'protection', 'Our', 'nanoparticle', 'technology', 'targets', 'antigens', 'conserved', 'epitopes', 'essential', 'viral', 'function', 'Our', 'vaccine', 'technology', 'potential', 'applied', 'broadly', 'wide', 'variety', 'human', 'infectious', 'diseases', 'Program', 'Current', 'Development', 'Stage', 'Respiratory', 'Syncytial', 'Virus', 'RSV', 'Infants', 'via', 'Maternal', 'Immunization', 'Phase', '3', 'Older', 'Adults', 'Phase', '2', 'Pediatrics', 'Phase', '1', 'Nanoparticle', 'Influenza', 'NanoFlu', 'Phase', '1/2', 'Combination', 'Influenza/RSV', 'Preclinical', 'Emerging', 'Viruses', 'Ebola', 'Virus', 'EBOV', 'Phase', '1', 'Zika', 'Virus', 'ZIKV', 'Preclinical', 'Supported', '89.1', 'million', 'grant', 'BMGF', 'A', 'current', 'summary', 'significant', 'research', 'development', 'programs', 'status', 'related', 'product', 'candidates', 'development', 'follows', 'Respiratory', 'Syncytial', 'Virus', 'We', 'identified', 'three', 'susceptible', 'target', 'populations', 'could', 'benefit', 'development', 'respiratory', 'syncytial', 'virus', 'fusion', 'F', 'protein', 'nanoparticle', 'vaccine', 'candidate', 'RSV', 'F', 'Vaccine', 'different', 'formulations', 'infants', 'via', 'maternal', 'immunization', 'older', 'adults', '60', 'years', 'age', 'older', 'children', 'six', 'months', 'five', 'years', 'age', 'pediatrics', 'We', 'believe', 'RSV', 'F', 'Vaccine', 'represents', 'multi-billion', 'dollar', 'revenue', 'opportunity', 'worldwide', 'Currently', 'approved', 'RSV', 'vaccine', 'available', '39', 'Repeat', 'infection', 'lifelong', 'susceptibility', 'RSV', 'common', 'currently', 'estimate', 'global', 'cost', 'burden', 'RSV', 'excess', '88', 'billion.1', 'Despite', 'decades', 'effort', 'develop', 'RSV', 'vaccine', 'currently', 'licensed', 'vaccines', 'We', 'made', 'breakthrough', 'developing', 'vaccine', 'targets', 'fusion', 'protein', 'F-protein', 'virus', 'The', 'F-protein', 'highly', 'conserved', 'amino', 'acid', 'sequences', 'called', 'antigenic', 'sites', 'believe', 'ideal', 'vaccine', 'targets', 'We', 'genetically', 'engineered', 'novel', 'F-protein', 'antigen', 'resulting', 'enhanced', 'immunogenicity', 'exposing', 'number', 'antigenic', 'sites', 'The', 'Novavax', 'RSV', 'F', 'Vaccine', 'assembles', 'recombinant', 'protein', 'nanoparticle', 'optimized', 'F-protein', 'antigen', 'presentation', 'We', 'seeking', 'bring', 'first', 'RSV', 'vaccine', 'market', 'combat', '64', 'million', 'RSV', 'infections', 'occur', 'globally', 'year.2,3', 'RSV', 'Infants', 'via', 'Maternal', 'Immunization', 'Program', 'Burden', 'Disease', 'RSV', 'common', 'cause', 'lower', 'respiratory', 'tract', 'infections', 'leading', 'viral', 'cause', 'severe', 'lower', 'respiratory', 'tract', 'disease', 'infants', 'young', 'children', 'worldwide.4,5', 'In', 'U.S', 'RSV', 'leading', 'cause', 'hospitalization', 'infants', 'globally', 'second', 'malaria', 'cause', 'death', 'children', 'one', 'year', 'age.6,7', 'Despite', 'induction', 'post-infection', 'immunity', 'repeat', 'infection', 'lifelong', 'susceptibility', 'RSV', 'common.8,9', 'Clinical', 'Trial', 'Update', 'Prepare', 'Phase', '3', 'Trial', 'Ongoing', 'We', 'initiated', 'Prepare', 'global', 'pivotal', 'Phase', '3', 'clinical', 'trial', 'RSV', 'F', 'Vaccine', 'using', 'aluminum', 'phosphate', 'adjuvant', 'approximately', '4,600', 'healthy', 'pregnant', 'women', 'December', '2015', 'The', 'primary', 'objective', 'Prepare', 'trial', 'determine', 'efficacy', 'maternal', 'immunization', 'RSV', 'F', 'Vaccine', 'symptomatic', 'RSV', 'lower', 'respiratory', 'tract', 'infection', 'objective', 'measures', 'medical', 'significance', 'infants', 'minimum', 'first', '90', 'days', 'life', 'first', 'six', 'months', 'life', 'The', 'Prepare', 'trial', 'utilizes', 'group', 'sequential', 'design', 'We', 'initiate', 'prescribed', 'interim', 'efficacy', 'analysis', 'approximately', '4,600', 'enrolled', 'women', 'currently', 'expected', 'mid-2018', 'report', 'results', 'interim', 'analysis', 'expected', 'early', '2019', 'Assuming', 'successful', 'interim', 'analysis', 'results', 'trial', 'would', 'concluded', 'without', 'enrollment', 'In', '2017', 'approximately', '1,300', 'participants', 'Prepare', 'trial', 'conducted', 'informational', 'analysis', 'provided', 'positive', 'indication', 'vaccine', 'potential', 'efficacy', '45', '100%10', 'de-risking', 'important', 'program', 'These', 'results', 'allowed', 'us', 'make', 'go-forward', 'decisions', 'relating', 'various', 'program-related', 'activities', 'The', 'Prepare', 'trial', 'supported', 'grant', 'Grant', '89.1', 'million', 'BMGF', 'The', 'Grant', 'supports', 'development', 'activities', 'product', 'licensing', 'efforts', 'World', 'Health', 'Organization', 'WHO', 'prequalification', 'RSV', 'F', 'Vaccine', 'In', '2015', 'along', 'Grant', 'agreement', 'Grant', 'Agreement', 'concurrently', 'entered', 'Global', 'Access', 'Commitments', 'Agreement', 'BMGF', 'agreed', 'make', 'certain', 'amount', 'RSV', 'F', 'Vaccine', 'available', 'accessible', 'affordable', 'pricing', 'people', 'certain', 'low', 'middle', 'income', 'countries', '1', 'Estimated', 'value', 'life', 'lost', 'future', 'health', 'implications', 'lost', 'earnings', 'preliminary', 'data', 'based', 'Novavax', 'research', 'available', 'epidemiology', 'health', 'outcomes', 'data', '2', 'Nair', 'H', 'et', 'al', '2010', 'Lancet', '375:1545', '1555', '3', 'WHO', 'Acute', 'Respiratory', 'Infections', 'September', '2009', 'Update', 'http', 'apps.who.int/vaccine_research/diseases/ari/en/index2.html', '4', 'Nair', 'H', 'et', 'al', '2010', 'Lancet', '375:1545', '1555', '5', 'CDC', 'https', 'www.cdc.gov/rsv/research/us-surveillance.html', '6', 'Hall', 'C.B', 'et', 'al', '2013', 'Pediatrics', '132(2', 'E341-348', '7', 'Oxford', 'Vaccine', 'Group', 'http', 'www.ovg.ox.ac.uk/rsv', '8', 'Glezen', 'W.P', 'et', 'al', '1986', 'Am', 'J', 'Dis', 'Child', '140:543-546', '9', 'Glenn', 'G.M', 'et', 'al', '2016', 'JID', '213(3', '411-12', '10', 'Assumes', '2:1', 'randomization', '40', 'Phase', '2', 'Safety', 'Immunogenicity', 'Trial', 'Completed', 'In', 'September', '2015', 'announced', 'positive', 'top-line', 'data', 'Phase', '2', 'clinical', 'trial', 'RSV', 'F', 'Vaccine', '50', 'healthy', 'pregnant', 'women', 'infants', 'This', 'clinical', 'trial', 'evaluated', 'safety', 'immunogenicity', 'RSV', 'F', 'Vaccine', 'pregnant', 'women', 'third', 'trimester', 'assessed', 'transplacental', 'transfer', 'maternal', 'antibodies', 'induced', 'vaccine', 'The', 'trial', 'also', 'examined', 'impact', 'maternal', 'immunization', 'infant', 'safety', 'first', 'year', 'life', 'RSV-specific', 'antibody', 'levels', 'infants', 'first', 'six', 'months', 'life', 'Immunized', 'women', 'demonstrated', 'geometric', 'mean', '14-fold', 'rise', 'anti-F', 'IgG', '29-fold', 'rise', 'palivizumab-competing', 'antibodies', '2.7', '2.1-fold', 'rises', 'microneutralization', 'titers', 'RSV/A', 'RSV/B', 'respectively', 'In', 'contrast', 'women', 'received', 'placebo', 'demonstrated', 'significant', 'change', 'antibody', 'levels', 'The', 'infants', 'antibody', 'levels', 'delivery', 'averaged', '90-100', 'mothers', 'levels', 'indicating', 'efficient', 'transplacental', 'transfer', 'antibodies', 'mother', 'infant', 'The', 'estimated', 'half-lives', 'infant', 'PCA', 'anti-F', 'IgG', 'RSV/A', 'RSV/B', 'microneutralizing', 'antibodies', 'based', 'data', 'day', '60', '41', '30', '36', '34', 'days', 'respectively', 'Fast', 'Track', 'Designation', 'The', 'FDA', 'granted', 'Fast', 'Track', 'designation', 'RSV', 'F', 'Vaccine', 'protection', 'infants', 'via', 'maternal', 'immunization', 'Fast', 'Track', 'designation', 'intended', 'products', 'treat', 'serious', 'life-threatening', 'diseases', 'conditions', 'demonstrate', 'potential', 'address', 'unmet', 'medical', 'needs', 'diseases', 'conditions', 'The', 'program', 'designed', 'facilitate', 'development', 'expedite', 'review', 'drugs', 'treat', 'serious', 'life-threatening', 'conditions', 'approved', 'products', 'reach', 'market', 'expeditiously', 'RSV', 'Older', 'Adults', 'Program', 'Burden', 'Disease', 'Older', 'adults', '60', 'years', 'age', 'older', 'increased', 'risk', 'RSV', 'disease', 'due', 'immunosenescence', 'age-related', 'decline', 'human', 'immune', 'system', 'In', 'population', 'RSV', 'important', 'respiratory', 'virus', 'distinct', 'influenza', 'frequently', 'responsible', 'serious', 'lower', 'respiratory', 'tract', 'disease', 'may', 'lead', 'hospitalization', 'even', 'death', 'Additionally', 'RSV', 'infection', 'lead', 'exacerbation', 'underlying', 'co-morbidities', 'chronic', 'obstructive', 'pulmonary', 'disease', 'COPD', 'asthma', 'congestive', 'heart', 'failure', 'In', 'U.S', 'incidence', 'rate', 'approximately', '2.5', 'million', 'infections', 'per', 'year', 'RSV', 'increasingly', 'recognized', 'significant', 'cause', 'morbidity', 'mortality', 'population', '64', 'million', 'older', 'adults.11,12', 'Based', 'analysis', 'published', 'literature', 'applied', '2014', 'U.S', 'population', 'estimates', 'disease', 'causes', '207,000', 'hospitalizations', '16,000', 'deaths', 'among', 'adults', 'older', '65.13,14', 'Annually', 'estimate', 'approximately', '900,000', 'medical', 'interventions', 'directly', 'caused', 'RSV', 'disease', 'across', 'populations.15,16', '11', 'Falsey', 'A.R', 'et', 'al', '2005', 'NEJM', '352:1749', '59', 'extrapolated', '2015', 'census', 'population', '12', 'Falsey', 'A.R', 'et', 'al', '1995', 'JID.172:389-94', '13', 'Falsey', 'A.R', 'et', 'al', '2005', 'NEJM', '352:1749', '59', 'extrapolated', '2015', 'census', 'population', '14', 'W.W', 'Thompson', 'et', 'al', 'Mortality', 'associated', 'influenza', 'respiratory', 'syncytial', 'virus', 'United', 'States', 'JAMA', '2003', '289(2', '179-186', '15', 'K', 'Widmer', 'et', 'al', 'Rates', 'hospitalizations', 'respiratory', 'syncytial', 'virus', 'human', 'metapneumovirus', 'influenza', 'virus', 'older', 'adults', 'J', 'Infect', 'Dis', '2012', '206', '56-62', '16', 'K', 'Widmer', 'et', 'al', 'Respiratory', 'syncytial', 'virus', 'human', 'metapneumovirus-associated', 'emergency', 'department', 'hospital', 'burden', 'adults', 'Influenza', 'Other', 'Respiratory', 'Viruses', '2014', '8(3', '347-352', '41', 'Clinical', 'Trial', 'Updates', 'Analyses', 'Phase', '2', 'E-205', 'Safety', 'Immunogenicity', 'Clinical', 'Trial', 'Completed', 'In', 'July', '2017', 'announced', 'positive', 'top-line', 'data', 'Phase', '2', 'clinical', 'trial', 'RSV', 'F', 'Vaccine', 'older', 'adults', 'known', 'E-205', 'The', 'objective', 'E-205', 'trial', 'assess', 'safety', 'immunogenicity', 'one', 'two', 'dose', 'regimens', 'RSV', 'F', 'Vaccine', 'without', 'aluminum', 'phosphate', 'proprietary', 'Matrix-M', 'adjuvant', 'older', 'adults', 'The', 'trial', 'randomized', 'observer-blinded', 'placebo-controlled', 'trial', 'enrolled', '300', 'older', 'adults', 'Southern', 'Hemisphere', 'Participants', 'enrolled', 'vaccinated', 'outside', 'RSV', 'season', 'best', 'assess', 'immunogenicity', 'Immunogenicity', 'results', 'indicated', 'aluminum', 'phosphate', 'Matrix-M', 'adjuvants', 'increased', 'magnitude', 'duration', 'quality', 'immune', 'response', 'relative', 'RSV', 'F', 'antigen', 'alone', 'All', 'formulations', 'regimens', 'safe', 'well-tolerated', 'The', 'data', 'support', 'inclusion', 'adjuvanted', 'formulations', 'RSV', 'F', 'Vaccine', 'future', 'older', 'adult', 'trials', 'although', 'currently', 'expect', 'initiate', 'trials', '2018', 'without', 'additional', 'funding', 'Further', 'Analyses', 'Prior', 'Clinical', 'Trials', 'Following', 'September', '2016', 'announcement', 'top-line', 'results', 'Resolve', 'Phase', '3', 'clinical', 'trial', 'RSV', 'F', 'Vaccine', 'older', 'adults', 'conducted', '2015-16', 'RSV', 'season', 'U.S', 'conducted', 'multiple', 'analyses', 'clinical', 'data', 'Resolve', 'trial', 'well', 'completed', 'Phase', '2', 'clinical', 'trials', 'conducted', 'older', 'adults', 'Our', 'analyses', 'clinical', 'trials', 'sought', 'better', 'understand', 'results', 'More', 'detailed', 'descriptions', 'RSV', 'older', 'adult', 'clinical', 'trials', 'found', 'Clinical', 'Trial', 'Updates', 'Analyses', 'trials', 'named', 'briefly', 'described', 'following', 'table', 'Clinical', 'Trial', 'Name', 'Phase', 'Description', 'Conducted', 'Participants', 'E-201', 'Phase', '2', 'Efficacy', 'prevention', 'symptomatic', 'RSV', 'disease', '2014-15', 'RSV', 'season', '1,600', 'Resolve', 'E-301', 'Phase', '3', 'Efficacy', 'prevention', 'msLRTD', '2015-16', 'RSV', 'season', '11,856', 'E-202', 'Rollover', 'Phase', '2', 'Immunogenicity', 'response', 'serial', 'immunization', 'E-201', '2015-16', 'RSV', 'season', '1,329', 'E-205', 'Phase', '2', 'Immunogenicity', 'one', 'two', 'doses', 'without', 'adjuvant', '2017', '300', 'We', 'found', 'seasonal', 'variation', 'attack', 'rate', 'meaning', 'incidence', 'infectious', 'disease', 'at-risk', 'population', 'may', 'large', 'impact', 'demonstrating', 'vaccine', 'efficacy', 'particular', 'year', 'Lower', 'attack', 'rates', 'may', 'mean', 'either', 'virus', 'less', 'common', 'given', 'season', 'alternatively', 'population', 'studied', 'increased', 'intrinsic', 'resistance', 'season', 'due', 'variety', 'potential', 'factors', 'recent', 'prior', 'exposure', 'In', 'E-201', 'trial', 'witnessed', 'high', 'attack', 'rate', 'showed', 'clear', 'demonstration', 'efficacy', 'In', 'Resolve', 'trial', 'following', 'year', 'observed', 'primary', 'endpoint', 'attack', 'rate', 'one-fourth', 'previous', 'season', 'This', 'scenario', 'represents', 'conundrum', 'influenza', 'vaccine', 'developers', 'experienced', 'decades', 'low', 'attack', 'rate', 'influenza', 'seasons', 'make', 'difficult', 'demonstrate', 'vaccine', 'efficacy', 'Additional', 'analyses', 'Resolve', 'trial', 'data', 'indicate', 'RSV', 'F', 'Vaccine', 'associated', '61', 'reduction', 'hospitalizations', 'due', 'COPD', 'exacerbations', 'analysis', 'E-201', 'trial', 'showed', 'similar', 'signal', 'supporting', 'finding', 'We', 'believe', 'higher-risk', 'patients', 'represent', 'unmet', 'medical', 'need', 'significant', 'healthcare', 'cost', 'burden', 'could', 'potentially', 'addressed', 'vaccine', '42', 'Resolve', 'E-301', 'Phase', '3', 'Trial', 'Completed', 'In', 'September', '2016', 'announced', 'top-line', 'data', 'Resolve', 'trial', 'Resolve', 'randomized', 'observer-blinded', 'placebo-controlled', 'trial', 'began', 'November', '2015', 'fully', 'enrolled', '11,856', 'older', 'adults', '60', 'sites', 'U.S', 'December', '2015', 'The', 'trial', 'meet', 'pre-specified', 'primary', 'secondary', 'efficacy', 'objectives', 'demonstrate', 'vaccine', 'efficacy', 'The', 'primary', 'objective', 'Resolve', 'trial', 'demonstrate', 'efficacy', 'prevention', 'moderate-severe', 'RSV', 'msLRTD', 'defined', 'presence', 'multiple', 'lower', 'respiratory', 'tract', 'symptoms', 'The', 'secondary', 'objective', 'trial', 'demonstrate', 'efficacy', 'RSV', 'F', 'Vaccine', 'reducing', 'incidence', 'symptomatic', 'respiratory', 'disease', 'due', 'RSV', 'ARD', 'The', 'trial', 'also', 'evaluated', 'safety', 'unadjuvanted', '135', 'microgram', 'dose', 'RSV', 'F', 'Vaccine', 'compared', 'placebo', 'Consistent', 'previous', 'clinical', 'experience', 'vaccine', 'well-tolerated', 'Phase', '2', 'E-202', 'Rollover', 'Trial', 'Completed', 'In', 'September', '2016', 'announced', 'positive', 'top-line', 'data', 'E-202', 'rollover', 'trial', 'RSV', 'F', 'Vaccine', 'older', 'adults', 'The', 'trial', 'randomized', 'observer-blinded', 'placebo-controlled', 'rollover', 'trial', 'enrolled', '1,329', 'older', 'adults', 'prior', 'E-201', 'trial', 'conducted', '10', 'sites', 'U.S', 'E-201', 'trial', 'The', 'primary', 'objectives', 'trial', 'evaluate', 'safety', 'serum', 'anti-F', 'IgG', 'antibody', 'concentrations', 'response', 'immunization', 'RSV', 'F', 'Vaccine', 'The', 'exploratory', 'objectives', 'trial', 'evaluated', 'efficacy', 'second', 'annual', 'dose', 'RSV', 'F', 'Vaccine', 'prevention', 'RSV', 'ARD', 'RSV', 'msLRTD', 'Participants', 'previously', 'randomized', 'receive', '135', 'microgram', 'RSV', 'F', 'Vaccine', 'placebo', 're-enrolled', 're-randomized', 'receive', 'either', '135', 'microgram', 'RSV', 'F', 'Vaccine', 'placebo', 'This', 'trial', 'design', 'resulted', 'four', 'separate', 'trial', 'arms', 'participants', 'receiving', 'placebo', 'first', 'trial', 'second', 'trial', 'Placebo-Placebo', 'b', 'participants', 'receiving', 'RSV', 'F', 'Vaccine', 'first', 'trial', 'placebo', 'second', 'trial', 'Vaccine-Placebo', 'c', 'participants', 'receiving', 'placebo', 'first', 'trial', 'RSV', 'F', 'Vaccine', 'second', 'trial', 'Placebo-Vaccine', 'participants', 'receiving', 'RSV', 'F', 'Vaccine', 'first', 'trial', 'second', 'trial', 'Vaccine-Vaccine', 'The', 'E-202', 'rollover', 'trial', 'demonstrated', 'immunogenicity', 'active', 'vaccine', 'recipients', '6-fold', 'increase', 'anti-F', 'IgG', 'Placebo-Vaccine', 'arm', 'consistent', 'E-201', 'trial', 'There', 'higher', 'anti-F', 'IgG', 'baseline', 'Vaccine-Vaccine', 'arm', 'compared', 'Placebo-Vaccine', 'arm', 'Vaccine-Vaccine', 'arm', 'showed', 'greater', '2-fold', 'increase', 'anti-F', 'IgG', 'higher', 'baseline', 'Phase', '2', 'E-201', 'Trial', 'Older', 'Adults', 'Completed', 'In', 'August', '2015', 'announced', 'positive', 'top-line', 'data', 'E-201', 'trial', 'RSV', 'F', 'Vaccine', '1,600', 'older', 'adults', 'The', 'E-201', 'trial', 'designed', 'prospectively', 'examine', 'incidence', 'symptomatic', 'respiratory', 'illnesses', 'associated', 'RSV', 'infection', 'community-living', 'older', 'adults', 'treated', 'placebo', 'The', 'trial', 'also', 'evaluated', 'safety', 'immunogenicity', 'RSV', 'F', 'Vaccine', 'compared', 'placebo', 'Finally', 'trial', 'estimated', 'efficacy', 'RSV', 'F', 'Vaccine', 'reducing', 'incidence', 'respiratory', 'illness', 'due', 'RSV', 'The', 'trial', 'first', 'demonstrate', 'efficacy', 'active', 'RSV', 'immunization', 'clinical', 'trial', 'population', 'In', 'per', 'protocol', 'population', 'clinical', 'trial', 'showed', 'statistically', 'significant', 'vaccine', 'efficacy', 'prevention', 'symptomatic', 'RSV', 'disease', '41', 'ad', 'hoc', 'analysis', 'showed', 'decrease', 'RSV', 'disease', 'symptoms', 'lower', 'respiratory', 'tract', 'infection', '45', 'older', 'adults', 'The', 'clinical', 'trial', 'established', 'attack', 'rate', 'symptomatic', 'RSV', 'disease', '4.9', 'older', 'adults', '95', 'included', 'lower', 'respiratory', 'track', 'symptoms', 'Efficacy', 'severe', 'RSV', 'illness', 'defined', 'presence', 'multiple', 'lower', 'respiratory', 'tract', 'symptoms', 'signs', 'associated', 'difficulty', 'breathing', '64', 'ad', 'hoc', 'analyses', '43', 'RSV', 'Pediatrics', 'Program', 'Burden', 'Disease', 'There', 'currently', 'approximately', '18', 'million', 'children', 'U.S', 'six', 'months', 'five', 'years', 'age.17', 'By', 'age', 'five', 'essentially', 'children', 'exposed', 'RSV', 'likely', 'developed', 'natural', 'immunity', 'virus', 'thus', 'decreasing', 'rate', 'severe', 'disease', 'children', 'In', 'U.S', 'RSV', 'responsible', 'approximately', '57,000', 'hospitalizations', 'children', 'five', 'years', 'age', 'annually', 'vast', 'majority', 'occur', 'infants', 'less', 'one', 'year', 'old', 'especially', 'six', 'months', 'age.18,19,20,21,22', 'Clinical', 'Trial', 'Update', 'In', 'September', '2015', 'announced', 'positive', 'top-line', 'data', 'Phase', '1', 'clinical', 'trial', 'RSV', 'F', 'Vaccine', 'healthy', 'children', 'two', 'six', 'years', 'age', 'This', 'clinical', 'trial', 'evaluated', 'safety', 'immunogenicity', 'RSV', 'F', 'Vaccine', 'one', 'two', 'doses', 'without', 'aluminum', 'phosphate', 'adjuvant', 'Trial', 'enrollment', 'concluded', 'smaller', 'planned', 'cohort', 'dosing', 'could', 'completed', 'ahead', '2014-15', 'RSV', 'season', 'The', 'vaccine', 'well-tolerated', 'serum', 'samples', 'collected', 'subset', '18', 'immunized', 'children', 'per-protocol', 'population', 'demonstrated', 'RSV', 'F', 'Vaccine', 'highly', 'immunogenic', 'formulations', 'regimens', 'There', 'greater', '10-fold', 'increases', 'anti-F', 'IgG', 'PCA', 'antibody', 'titers', 'adjuvanted', 'group', 'greater', '6-fold', 'increases', 'anti-F', 'IgG', 'PCA', 'antibody', 'titers', 'unadjuvanted', 'group', 'Development', 'RSV', 'F', 'Vaccine', 'pediatrics', 'would', 'likely', 'follow', 'successful', 'development', 'RSV', 'F', 'Vaccine', 'maternal', 'immunization', 'Influenza', 'Burden', 'Disease', 'Influenza', 'world-wide', 'infectious', 'disease', 'causes', 'illness', 'humans', 'ranging', 'mild', 'life-threatening', 'symptoms', 'even', 'death', 'Serious', 'illness', 'occurs', 'susceptible', 'populations', 'pediatrics', 'older', 'adults', 'also', 'general', 'population', 'largely', 'infection', 'unique', 'strains', 'influenza', 'humans', 'developed', 'protective', 'antibodies', 'Current', 'estimates', 'seasonal', 'influenza', 'vaccine', 'growth', 'top', 'seven', 'markets', 'U.S', 'Japan', 'France', 'Germany', 'Italy', 'Spain', 'UK', 'show', 'potential', 'increase', 'approximately', '3.2', 'billion', '2012-13', 'season', '5.3', 'billion', '2021-22', 'season.23', 'The', 'Advisory', 'Committee', 'Immunization', 'Practices', 'Center', 'Disease', 'Control', 'Prevention', 'CDC', 'recommends', 'persons', 'aged', 'six', 'months', 'older', 'vaccinated', 'annually', 'seasonal', 'influenza', 'Influenza', 'major', 'burden', 'public', 'health', 'worldwide', 'estimated', 'one', 'million', 'deaths', 'year', 'attributed', 'influenza.24', 'It', 'estimated', 'year', 'influenza', 'attacks', '5', '10', 'adults', '20', '30', 'children', 'causing', 'significant', 'levels', 'illness', 'hospitalization', 'death.25', 'One', 'important', 'advantage', 'recombinant', 'seasonal', 'influenza', 'vaccines', 'like', 'candidate', 'developing', 'licensed', 'commercial', 'sale', 'large', 'quantities', 'vaccine', 'could', 'potentially', 'manufactured', 'quickly', 'cost-effective', 'manner', 'without', 'use', 'either', 'live', 'influenza', 'virus', 'eggs', 'Our', 'recombinant', 'influenza', 'nanoparticles', 'also', 'display', 'conserved', 'antigenic', 'regions', 'potential', 'elicit', 'broadly', 'neutralizing', 'antibodies', 'appear', 'protect', 'range', 'drifted', 'strains', 'influenza', 'strains', 'time', 'hemagglutinin', 'antigen', 'undergoes', 'accumulation', 'genetic', 'mutations', 'hemagglutinin', 'antigen', 'sites', 'bind', 'neutralizing', 'antibodies', 'potentially', 'resulting', 'reduced', 'protection', 'antibodies', 'Additionally', 'nanoparticles', 'offer', 'improved', 'purity', 'manufacturability', 'advantages', 'co-formulation', 'nanoparticle-based', 'vaccines', '17', 'U.S', 'Census', 'www.census.go/population/international/data/idb/informationGateway.php', '18', 'Stockman', 'L.J', 'et', 'al', '2012', 'Pediatr', 'Infect', 'Dis', 'J', '31', '5-9', '19', 'CDC', 'update', 'May', '5', '2015', 'http', 'www.cdc.gov/rsv/research/us-surveillance.html', '20', 'Boyce', 'T.G', 'et', 'al', '2000', 'Pediatrics', '137', '865-870', '21', 'Hall', 'C.B', 'et', 'al', '2009', 'NEJM', '360(6', '588-98', '22', 'Hall', 'C.B', 'et', 'al', '2013', 'Pediatrics', '132(2', 'E341-8', '23', 'Influenza', 'Vaccines', 'Forecasts', 'Datamonitor', '2013', '24', 'Resolution', 'World', 'Health', 'Assembly', '2003', 'WHA56.19', '28', '25', 'WHO', 'position', 'paper', '2012', 'Weekly', 'Epidemiol', 'Record', '87(47', '461', '76', '44', 'Clinical', 'Trial', 'Update', 'In', 'February', '2018', 'reported', 'positive', 'top-line', 'results', 'Phase', '1/2', 'clinical', 'trial', 'nanoparticle', 'seasonal', 'influenza', 'vaccine', 'candidate', 'including', 'proprietary', 'Matrix-M', 'adjuvant', 'NanoFlu', 'vaccine', 'older', 'adults', 'initiated', 'September', '2017', 'The', 'trial', 'randomized', 'observer-blinded', 'active', 'comparator-controlled', 'trial', 'approximately', '330', 'healthy', 'older', 'adults', 'The', 'primary', 'objective', 'trial', 'assess', 'safety', 'immunogenicity', 'two', 'concentrations', '15', 'micrograms', '60', 'micrograms', 'NanoFlu', 'vaccine', 'compared', 'leading', 'licensed', 'egg-based', 'high-dose', 'influenza', 'vaccine', 'older', 'adults', 'IIV3-HD', 'Key', 'findings', 'trial', 'include', 'NanoFlu', 'vaccine', 'induced', 'Significantly', 'higher', 'hemagglutination', 'inhibition', 'HAI', 'antibody', 'responses', 'homologous', 'H1N1', 'H3N2', 'influenza', 'viruses', 'comparable', 'HAI', 'responses', 'homologous', 'B/Brisbane', 'strain', 'Significantly', 'higher', 'HAI', 'immune', 'responses', 'historic', 'forward-drifted', 'H3N2', 'virus', 'strains', 'Strong', 'neutralizing', 'antibody', 'responses', 'correlate', 'HAI', 'results', 'Overall', 'NanoFlu', 'vaccine', 'well-tolerated', 'three-week', 'trial', 'period', 'Given', 'strength', 'trial', 'results', 'submitted', 'publication', 'peer-reviewed', 'medical', 'journal', 'and/or', 'presentation', 'upcoming', 'scientific', 'meeting', 'Based', 'results', 'expect', 'begin', 'Phase', '2', 'trial', 'NanoFlu', 'vaccine', 'third', 'quarter', '2018', 'Preclinical', 'Analyses', 'Preclinical', 'data', 'NanoFlu', 'compared', 'head-to-head', 'challenge', 'study', 'IIV3-HD', 'well', 'IIV3-SD', 'standard', 'dose', 'seasonal', 'influenza', 'vaccine', 'announced', 'August', '2017', 'provided', 'strong', 'rationale', 'initiation', 'Phase', '1/2', 'trial', 'Our', 'NanoFlu', 'vaccine', 'demonstrated', 'significantly', 'stronger', 'broader', 'immune', 'responses', 'microneutralizing', 'antibodies', 'homologous', 'heterologous', 'influenza', 'strains', 'including', 'series', 'drifted', 'H3N2', 'strains', 'evolved', 'across', 'decade', 'influenza', 'seasons', 'In', 'preclinical', 'challenge', 'study', 'showed', 'NanoFlu', 'vaccine', 'protective', 'licensed', 'comparator', 'vaccines', 'homologous', 'H3N2', 'virus', 'ten-year', 'old', 'drifted', 'H3N2', 'strain', 'In', 'parallel', 'announced', 'achievement', 'significant', 'improvements', 'manufacturing', 'yields', 'product', 'purity', 'Emerging', 'Viruses', 'Ebola', 'Virus', 'EBOV', 'formerly', 'known', 'Ebola', 'hemorrhagic', 'fever', 'severe', 'often', 'fatal', 'illness', 'humans', 'Multiple', 'strains', 'EBOV', 'identified', 'recent', 'Makona', 'EBOV', 'strain', 'associated', 'case', 'fatality', 'rate', '50', '90', '26', 'There', 'currently', 'licensed', 'treatments', 'proven', 'neutralize', 'virus', 'range', 'blood', 'immunological', 'drug', 'therapies', 'development', 'Despite', 'development', 'therapies', 'current', 'vaccine', 'approaches', 'target', 'either', 'previous', 'strain', 'virus', 'initially', 'developed', 'delivered', 'genetic', 'vectors', 'In', 'contrast', 'EBOV', 'glycoprotein', 'vaccine', 'candidate', 'Ebola', 'GP', 'Vaccine', 'developed', 'using', 'Makona', 'EBOV', 'strain', '26', 'WHO', 'http', 'www.who.int/mediacentre/factsheets/fs103/en', '45', 'In', 'July', '2015', 'announced', 'positive', 'top-line', 'data', 'Phase', '1', 'clinical', 'trial', 'Ebola', 'GP', 'Vaccine', 'ascending', 'doses', 'without', 'Matrix-M', 'adjuvant', '230', 'healthy', 'adults', 'Participants', 'received', 'either', 'one', 'two', 'intramuscular', 'injections', 'ranging', '6.5', 'micrograms', '50', 'micrograms', 'antigen', 'without', 'adjuvant', 'placebo', 'Immunogenicity', 'assessed', 'multiple', 'time', 'points', 'including', 'days', '28', '35', 'These', 'Phase', '1', 'data', 'demonstrated', 'Ebola', 'GP', 'Vaccine', 'highly', 'immunogenic', 'well-tolerated', 'conjunction', 'proprietary', 'Matrix-M', 'adjuvant', 'resulted', 'significant', 'antigen', 'dose-sparing', 'The', 'adjuvanted', 'Ebola', 'GP', 'Vaccine', 'highly', 'immunogenic', 'dose', 'levels', 'adjuvanted', 'two-dose', 'regimens', 'induced', 'Ebola', 'anti-GP', 'antibody', 'geometric', 'mean', 'responses', '45,000', '70,000', 'ELISA', 'units', 'representing', '500', '750-fold', 'rise', 'baseline', 'day', '35', 'In', '2015', 'also', 'announced', 'successful', 'data', 'two', 'separate', 'non-human', 'primate', 'challenge', 'studies', 'Ebola', 'GP', 'Vaccine', 'cases', 'challenge', 'lethal', 'control', 'animal', 'whereas', '100', 'immunized', 'animals', 'protected', 'Zika', 'Virus', 'We', 'initiated', 'development', 'vaccine', 'Zika', 'virus', 'ZIKV', 'response', 'unmet', 'global', 'medical', 'need', 'response', 'serious', 'disease', 'The', 'subsequent', 'evolving', 'epidemiology', 'ZIKV', 'saw', 'significant', 'reductions', 'cases', 'U.S', 'around', 'world', '2017', 'along', 'uncertainty', 'governmental', 'non-governmental', 'organization', 'funding', 'caused', 'us', 'suspend', 'development', 'efforts', 'lieu', 'competing', 'resources', 'corporate', 'priorities', 'around', 'promising', 'product', 'development', 'Combination', 'Respiratory', 'Vaccine', 'Given', 'ongoing', 'development', 'RSV', 'F', 'Vaccine', 'desire', 'develop', 'combination', 'respiratory', 'vaccine', 'potential', 'protect', 'RSV', 'seasonal', 'influenza', 'made', 'decision', 'shift', 'seasonal', 'influenza', 'vaccine', 'development', 'focus', 'VLP-based', 'seasonal', 'influenza', 'vaccines', 'nanoparticle-based', 'seasonal', 'influenza', 'vaccines', 'We', 'remain', 'confident', 'combination', 'nanoparticle', 'vaccine', 'RSV', 'influenza', 'feasible', 'CPLB', 'Joint', 'Venture', 'India', 'CPL', 'Biologicals', 'Private', 'Limited', 'CPLB', 'joint', 'venture', 'company', 'Cadila', 'Pharmaceuticals', 'Limited', 'Cadila', 'India', 'actively', 'developing', 'number', 'vaccine', 'candidates', 'genetically', 'engineered', 'us', 'CPLB', 'owned', '20', 'us', '80', 'Cadila', 'CPLB', 'operates', 'manufacturing', 'facility', 'India', 'production', 'vaccines', 'Seasonal', 'Influenza', 'Since', '2016', 'CPLB', 'marketing', 'CadiFlu-S', 'trivalent', 'VLP', 'influenza', 'vaccine', 'India', 'limited', 'sales', '2017', 'expected', '2018', 'Rabies', 'In', 'October', '2016', 'CPLB', 'initiated', 'Phase', '3', 'clinical', 'trial', 'India', 'recombinant', 'rabies', 'G', 'protein', 'vaccine', 'candidate', 'administered', 'prophylactic', 'regimens', 'pre', 'post-exposure', 'The', 'post-exposure', 'regimen', 'potential', 'use', 'fewer', 'doses', 'three', 'doses', 'current', 'standard', 'care', 'five', 'doses', 'Data', 'trial', 'expected', '2018', '46', 'Sales', 'Common', 'Stock', 'In', 'January', '2017', 'entered', 'At', 'Market', 'Issuance', 'Sales', 'Agreement', 'January', '2017', 'Sales', 'Agreement', 'allowed', 'us', 'issue', 'sell', '75', 'million', 'gross', 'proceeds', 'common', 'stock', 'During', '2017', 'sold', '50.9', 'million', 'shares', 'common', 'stock', 'January', '2017', 'Sales', 'Agreement', 'resulting', '63.4', 'million', 'net', 'proceeds', 'weighted', 'average', 'sales', 'price', '1.27', 'per', 'share', 'From', 'January', '1', 'January', '17', '2018', 'sold', '6.8', 'million', 'shares', 'common', 'stock', 'resulting', '10.3', 'million', 'net', 'proceeds', 'The', 'January', '2017', 'Sales', 'Agreement', 'fully', 'utilized', 'time', 'In', 'December', '2017', 'entered', 'At', 'Market', 'Issuance', 'Sales', 'Agreement', 'December', '2017', 'Sales', 'Agreement', 'allows', 'us', 'issue', 'sell', '75', 'million', 'gross', 'proceeds', 'common', 'stock', 'From', 'January', '17', '2018', 'March', '9', '2018', 'sold', '12.7', 'million', 'shares', 'common', 'stock', 'resulting', '26.0', 'million', 'net', 'proceeds', 'leaving', '48.6', 'million', 'remaining', 'Critical', 'Accounting', 'Policies', 'Use', 'Estimates', 'The', 'discussion', 'analysis', 'financial', 'condition', 'results', 'operations', 'based', 'upon', 'consolidated', 'financial', 'statements', 'prepared', 'accordance', 'accounting', 'principles', 'generally', 'accepted', 'United', 'States', 'The', 'preparation', 'consolidated', 'financial', 'statements', 'requires', 'us', 'make', 'estimates', 'assumptions', 'judgments', 'affect', 'reported', 'amounts', 'assets', 'liabilities', 'equity', 'disclosure', 'contingent', 'assets', 'liabilities', 'date', 'financial', 'statements', 'reported', 'amounts', 'revenue', 'expenses', 'reporting', 'period', 'These', 'estimates', 'particularly', 'estimates', 'relating', 'accounting', 'revenue', 'valuation', 'marketable', 'securities', 'stock-based', 'compensation', 'long-lived', 'assets', 'goodwill', 'material', 'impact', 'consolidated', 'financial', 'statements', 'discussed', 'detail', 'throughout', 'analysis', 'results', 'operations', 'discussed', 'We', 'base', 'estimates', 'historical', 'experience', 'various', 'assumptions', 'believe', 'reasonable', 'circumstances', 'results', 'form', 'basis', 'making', 'judgments', 'carrying', 'value', 'assets', 'liabilities', 'equity', 'readily', 'apparent', 'sources', 'Actual', 'results', 'outcomes', 'could', 'differ', 'estimates', 'assumptions', 'Revenue', 'We', 'recognize', 'revenue', 'research', 'contracts', 'contract', 'executed', 'contract', 'price', 'fixed', 'determinable', 'delivery', 'services', 'products', 'occurred', 'collection', 'contract', 'price', 'reasonably', 'assured', 'Payments', 'received', 'advance', 'work', 'performed', 'recorded', 'deferred', 'revenue', 'losses', 'contracts', 'recognized', 'period', 'become', 'known', 'We', 'historically', 'performed', 'research', 'development', 'U.S', 'Government', 'agencies', 'cost', 'reimbursable', 'fixed-fee', 'contracts', 'Under', 'cost', 'reimbursable', 'fixed-fee', 'contracts', 'reimbursed', 'recognized', 'revenue', 'allowable', 'costs', 'incurred', 'plus', 'portion', 'fixed-fee', 'earned', 'We', 'consider', 'fixed-fees', 'cost', 'reimbursable', 'contracts', 'earned', 'proportion', 'allowable', 'costs', 'incurred', 'performance', 'work', 'compared', 'total', 'estimated', 'contract', 'costs', 'costs', 'incurred', 'representing', 'reasonable', 'measurement', 'proportional', 'performance', 'work', 'completed', 'Under', 'HHS', 'BARDA', 'contract', 'certain', 'activities', 'pre-approved', 'HHS', 'BARDA', 'order', 'costs', 'deemed', 'allowable', 'direct', 'costs', 'Direct', 'costs', 'incurred', 'cost', 'reimbursable', 'contracts', 'recorded', 'research', 'development', 'expenses', 'Payments', 'us', 'cost', 'reimbursable', 'contracts', 'HHS', 'BARDA', 'contract', 'provisional', 'payments', 'subject', 'adjustment', 'upon', 'audit', 'government', 'An', 'audit', 'indirect', 'rates', 'U.S', 'government', 'years', 'ended', 'December', '31', '2011', '2012', 'completed', 'first', 'quarter', '2014', 'resulted', '7.7', 'million', 'revenue', 'recognized', '2015', 'relating', 'recovery', 'additional', 'costs', 'settlement', 'indirect', 'rates', 'years', 'collection', 'amount', 'became', 'reasonably', 'assured', 'An', 'audit', 'indirect', 'rates', 'years', 'ended', 'December', '31', '2013', '2014', 'completed', 'first', 'quarter', '2017', 'When', 'final', 'determination', 'additional', 'costs', 'years', 'ended', 'December', '31', '2013', '2014', 'made', 'amount', 'known', 'collection', 'amount', 'reasonably', 'assured', 'revenue', 'billings', 'adjusted', 'accordingly', '47', 'Under', 'Grant', 'Agreement', 'BMGF', 'reimbursed', 'certain', 'costs', 'support', 'development', 'activities', 'including', 'global', 'Phase', '3', 'clinical', 'trial', 'pregnant', 'women', 'third', 'trimester', 'product', 'licensing', 'efforts', 'efforts', 'obtain', 'WHO', 'prequalification', 'RSV', 'F', 'Vaccine', 'Payments', 'received', 'Grant', 'Agreement', 'deferred', 'recognized', 'revenue', 'research', 'development', 'activities', 'performed', 'We', 'analyze', 'grant', 'agreements', 'determine', 'whether', 'payments', 'received', 'recorded', 'revenue', 'reduction', 'research', 'development', 'expenses', 'In', 'reaching', 'determination', 'management', 'considers', 'number', 'factors', 'including', 'whether', 'principal', 'arrangement', 'whether', 'arrangement', 'significant', 'part', 'core', 'operations', 'Historically', 'payments', 'received', 'grant', 'agreements', 'recognized', 'revenue', 'since', 'act', 'principal', 'arrangement', 'activities', 'core', 'operations', 'Revenue', 'associated', 'upfront', 'payments', 'arrangements', 'recognized', 'contract', 'term', 'obligations', 'associated', 'upfront', 'payment', 'satisfied', 'Marketable', 'Securities', 'Our', 'marketable', 'securities', 'classified', 'available-for-sale', 'securities', 'carried', 'fair', 'value', 'Unrealized', 'gains', 'losses', 'securities', 'determined', 'other-than-temporary', 'included', 'accumulated', 'comprehensive', 'income', 'loss', 'stockholders', 'deficit', 'Investments', 'evaluated', 'periodically', 'determine', 'whether', 'decline', 'value', 'other-than-temporary', 'Management', 'reviews', 'criteria', 'magnitude', 'duration', 'decline', 'well', 'Company', 'ability', 'hold', 'securities', 'market', 'recovery', 'predict', 'whether', 'loss', 'value', 'other-than-temporary', 'If', 'decline', 'value', 'determined', 'other-than-temporary', 'value', 'security', 'reduced', 'impairment', 'recorded', 'statements', 'operations', 'For', 'marketable', 'securities', 'carried', 'fair', 'value', 'disclose', 'level', 'within', 'fair', 'value', 'hierarchy', 'prescribed', 'Accounting', 'Standard', 'Codification', 'ASC', 'Topic', '820', 'Fair', 'Value', 'Measurements', 'Disclosures', 'We', 'evaluate', 'types', 'securities', 'investment', 'portfolio', 'determine', 'proper', 'classification', 'fair', 'value', 'hierarchy', 'based', 'trading', 'activity', 'market', 'inputs', 'We', 'generally', 'obtain', 'information', 'independent', 'third-party', 'help', 'us', 'determine', 'fair', 'value', 'securities', 'Level', '2', 'fair', 'value', 'hierarchy', 'Investment', 'income', 'recorded', 'earned', 'included', 'investment', 'income', 'Stock-Based', 'Compensation', 'We', 'account', 'stock-based', 'compensation', 'equity', 'compensation', 'plans', 'accordance', 'ASC', 'Topic', '718', 'Compensation-Stock', 'Compensation', 'This', 'standard', 'requires', 'us', 'measure', 'cost', 'employee', 'services', 'received', 'exchange', 'equity', 'awards', 'based', 'grant-date', 'fair', 'value', 'award', 'Employee', 'stock-based', 'compensation', 'estimated', 'date', 'grant', 'based', 'award', 'fair', 'value', 'using', 'Black-Scholes', 'option-pricing', 'model', 'recognized', 'expense', 'straight-line', 'basis', 'requisite', 'service', 'period', 'awards', 'expected', 'vest', 'The', 'Black-Scholes', 'option-pricing', 'model', 'requires', 'use', 'certain', 'assumptions', 'significant', 'estimates', 'expected', 'volatility', 'market', 'price', 'common', 'stock', 'expected', 'term', 'award', 'Our', 'estimate', 'expected', 'volatility', 'based', 'historical', 'volatility', 'look-back', 'period', 'corresponding', 'expected', 'term', 'The', 'expected', 'term', 'represents', 'period', 'stock-based', 'awards', 'expected', 'outstanding', 'We', 'estimate', 'amount', 'based', 'historical', 'experience', 'similar', 'awards', 'giving', 'consideration', 'contractual', 'terms', 'awards', 'vesting', 'requirements', 'expectation', 'future', 'employee', 'behavior', 'including', 'post-vesting', 'exercise', 'forfeiture', 'history', 'We', 'review', 'valuation', 'assumptions', 'grant', 'date', 'result', 'assumptions', 'future', 'periods', 'may', 'change', 'Also', 'accounting', 'estimate', 'stock-based', 'compensation', 'expense', 'reasonably', 'likely', 'change', 'period', 'period', 'equity', 'awards', 'made', 'adjusted', 'cancellations', '48', 'Impairments', 'Long-Lived', 'Assets', 'We', 'account', 'impairment', 'long-lived', 'assets', 'including', 'finite-lived', 'intangible', 'assets', 'performing', 'evaluation', 'recoverability', 'carrying', 'value', 'long-lived', 'asset', 'group', 'whenever', 'events', 'changes', 'circumstances', 'indicate', 'carrying', 'value', 'asset', 'group', 'may', 'recoverable', 'Examples', 'events', 'changes', 'circumstances', 'indicate', 'recoverability', 'carrying', 'value', 'asset', 'group', 'assessed', 'include', 'limited', 'following', 'significant', 'decrease', 'market', 'value', 'asset', 'significant', 'change', 'extent', 'manner', 'asset', 'used', 'significant', 'physical', 'change', 'asset', 'significant', 'adverse', 'change', 'legal', 'factors', 'business', 'climate', 'could', 'affect', 'value', 'asset', 'adverse', 'action', 'assessment', 'regulator', 'accumulation', 'costs', 'significantly', 'excess', 'amount', 'originally', 'expected', 'acquire', 'construct', 'asset', 'current', 'period', 'operating', 'cash', 'flow', 'loss', 'combined', 'history', 'operating', 'cash', 'flow', 'losses', 'and/or', 'projection', 'forecast', 'demonstrates', 'continuing', 'losses', 'associated', 'asset', 'used', 'purpose', 'producing', 'revenue', 'We', 'consider', 'historical', 'performance', 'anticipated', 'future', 'results', 'evaluation', 'potential', 'impairment', 'Accordingly', 'indicators', 'impairment', 'present', 'evaluate', 'carrying', 'value', 'assets', 'group', 'relation', 'operating', 'performance', 'business', 'future', 'undiscounted', 'cash', 'flows', 'expected', 'result', 'use', 'asset', 'groups', 'Impairment', 'losses', 'recognized', 'sum', 'expected', 'future', 'cash', 'flows', 'less', 'assets', 'group', 'carrying', 'value', 'Goodwill', 'Goodwill', 'subject', 'impairment', 'tests', 'annually', 'frequently', 'indicators', 'impairment', 'arise', 'The', 'Company', 'determined', 'since', 'business', 'development', 'recombinant', 'vaccines', 'operates', 'single', 'operating', 'segment', 'one', 'reporting', 'unit', 'The', 'Company', 'primarily', 'utilizes', 'market', 'approach', 'considered', 'necessary', 'income', 'approach', 'determine', 'impairment', 'goodwill', 'The', 'market', 'approach', 'based', 'market', 'value', 'invested', 'capital', 'To', 'ensure', 'Company', 'capital', 'stock', 'appropriate', 'measurement', 'fair', 'value', 'Company', 'considers', 'factors', 'trading', 'volume', 'diversity', 'investors', 'analyst', 'coverage', 'If', 'considered', 'necessary', 'income', 'approach', 'used', 'confirming', 'look', 'market', 'approach', 'Goodwill', 'impairment', 'may', 'exist', 'carrying', 'value', 'reporting', 'unit', 'exceeds', 'estimated', 'fair', 'value', 'If', 'carrying', 'value', 'reporting', 'unit', 'exceeds', 'fair', 'value', 'step', 'two', 'impairment', 'analysis', 'performed', 'In', 'step', 'two', 'analysis', 'impairment', 'loss', 'recorded', 'equal', 'excess', 'carrying', 'value', 'reporting', 'unit', 'goodwill', 'implied', 'fair', 'value', 'circumstance', 'arise', 'At', 'December', '31', '2017', '2016', 'Company', 'used', 'market', 'approach', 'determine', 'Company', 'impairment', 'goodwill', 'The', 'fair', 'value', 'Company', 'single', 'reporting', 'unit', 'substantially', 'higher', 'carrying', 'value', 'resulting', 'impairment', 'goodwill', 'December', '31', '2017', '2016', 'Recent', 'Accounting', 'Pronouncements', 'See', 'Note', '3', 'Summary', 'Significant', 'Accounting', 'Policies', 'included', 'Notes', 'Consolidated', 'Financial', 'Statements', 'caption', 'Recent', 'Accounting', 'Pronouncements', 'Results', 'Operations', 'Fiscal', 'Years', '2017', '2016', '2015', 'amounts', 'tables', 'presented', 'thousands', 'except', 'per', 'share', 'information', 'The', 'following', 'discussion', 'historical', 'financial', 'condition', 'results', 'operations', 'Novavax', 'including', 'Novavax', 'AB', 'operations', 'read', 'conjunction', 'consolidated', 'financial', 'statements', 'notes', 'thereto', 'set', 'forth', 'Annual', 'Report', 'Additional', 'information', 'concerning', 'factors', 'could', 'cause', 'actual', 'results', 'differ', 'materially', 'forward-looking', 'statements', 'described', 'Part', 'I', 'Item', '1A', 'Risk', 'Factors', 'Annual', 'Report', '49', 'Revenue', '2017', '2016', '2015', 'Change', '2016', '2017', 'Change', '2015', '2016', 'Revenue', 'Total', 'revenue', '31,176', '15,353', '36,250', '15,823', '20,897', 'Revenue', '2017', '31.2', 'million', 'compared', '15.4', 'million', '2016', 'increase', '15.8', 'million', '103', 'Revenue', '2017', '2016', 'primarily', 'comprised', 'services', 'performed', 'Grant', 'Agreement', 'much', 'lesser', 'extent', 'HHS', 'BARDA', 'contract', 'revenue', 'Novavax', 'AB', 'Revenue', 'increased', 'Grant', 'Agreement', 'amount', '18.8', 'million', 'result', 'increased', 'enrollment', 'participants', 'Prepare', 'trial', 'partially', 'offset', '2.2', 'million', 'decreased', 'revenue', 'services', 'performed', 'HHS', 'BARDA', 'contract', 'expired', 'accordance', 'terms', 'September', '2016', 'Revenue', '2016', '15.4', 'million', 'compared', '36.3', 'million', '2015', 'decrease', '20.9', 'million', '58', 'Revenue', '2016', '2015', 'primarily', 'comprised', 'services', 'performed', 'Grant', 'Agreement', 'HHS', 'BARDA', 'contract', 'much', 'lesser', 'extent', 'PATH', 'Vaccine', 'Solutions', 'clinical', 'development', 'agreement', 'revenue', 'Novavax', 'AB', 'The', 'decrease', 'revenue', 'primarily', 'due', 'reduction', 'revenue', 'HHS', 'BARDA', 'contract', '31.2', 'million', 'due', 'lower', 'level', 'activity', '2016', 'compared', '2015', '7.7', 'million', 'recognized', '2015', 'recovery', 'additional', 'costs', 'settlement', 'indirect', 'rates', 'years', 'ended', 'December', '31', '2011', '2012', '3.1', 'million', 'relating', 'Phase', '2', 'clinical', 'trial', 'quadrivalent', 'seasonal', 'influenza', 'VLP', 'vaccine', 'candidate', 'Australia', '205', 'Trial', 'collection', 'amount', 'became', 'reasonably', 'assured', '2015', 'This', 'decrease', 'revenue', 'partially', 'offset', 'increase', '9.4', 'million', 'revenue', 'recorded', 'Grant', 'Agreement', 'relating', 'ongoing', 'RSV', 'F', 'Vaccine', 'Phase', '3', 'clinical', 'trial', 'protection', 'infants', 'via', 'maternal', 'immunization', 'We', 'expect', 'revenue', '2018', 'Grant', 'Agreement', 'higher', '2017', 'continue', 'enroll', 'participants', 'Prepare', 'Expenses', '2017', '2016', '2015', 'Change', '2016', '2017', 'Change', '2015', '2016', 'Expenses', 'Research', 'development', '168,435', '237,939', '162,644', '69,504', '75,295', 'General', 'administrative', '34,451', '46,527', '30,842', '12,076', '15,685', 'Total', 'expenses', '202,886', '284,466', '193,486', '81,580', '90,980', 'Research', 'Development', 'Expenses', 'Research', 'development', 'expenses', 'include', 'salaries', 'stock-based', 'compensation', 'laboratory', 'supplies', 'consultants', 'subcontractors', 'including', 'external', 'contract', 'research', 'organizations', 'expenses', 'associated', 'process', 'development', 'manufacturing', 'clinical', 'regulatory', 'quality', 'assurance', 'activities', 'programs', 'In', 'addition', 'indirect', 'costs', 'fringe', 'benefits', 'overhead', 'expenses', 'related', 'research', 'development', 'activities', 'also', 'included', 'research', 'development', 'expenses', 'Research', 'development', 'expenses', 'decreased', '168.4', 'million', '2017', '237.9', 'million', '2016', 'decrease', '69.5', 'million', '29', 'The', 'decrease', 'research', 'development', 'expenses', 'primarily', 'due', 'reduced', 'development', 'activities', 'RSV', 'F', 'Vaccine', 'older', 'adults', 'lower', 'employee-related', 'costs', 'At', 'December', '31', '2017', '300', 'employees', 'dedicated', 'research', 'development', 'programs', 'versus', '322', 'employees', 'December', '31', '2016', 'For', '2018', 'expect', 'increase', 'research', 'development', 'expenses', 'primarily', 'due', 'higher', 'anticipated', 'costs', 'support', 'product', 'development', 'RSV', 'F', 'Vaccine', 'potential', 'vaccine', 'candidates', '50', 'Research', 'development', 'expenses', 'increased', '237.9', 'million', '2016', '162.6', 'million', '2015', 'increase', '75.3', 'million', '46', 'The', 'increase', 'research', 'development', 'expenses', 'primarily', 'due', 'increased', 'costs', 'associated', 'RSV', 'F', 'Vaccine', 'clinical', 'trials', 'higher', 'employee-related', 'costs', 'including', 'increased', 'non-cash', 'stock-based', 'compensation', '4.4', 'million', 'Expenses', 'Functional', 'Area', 'We', 'track', 'research', 'development', 'expenses', 'type', 'costs', 'incurred', 'identifying', 'developing', 'manufacturing', 'testing', 'vaccine', 'candidates', 'We', 'evaluate', 'prioritize', 'activities', 'according', 'functional', 'area', 'therefore', 'believe', 'project-by-project', 'information', 'would', 'form', 'reasonable', 'basis', 'disclosure', 'investors', 'Historically', 'account', 'internal', 'research', 'development', 'expenses', 'project', 'since', 'employees', 'work', 'time', 'spread', 'across', 'multiple', 'programs', 'internal', 'manufacturing', 'clean-room', 'facility', 'produces', 'multiple', 'vaccine', 'candidates', 'The', 'following', 'summarizes', 'research', 'development', 'expenses', 'functional', 'area', 'years', 'ended', 'December', '31', '2017', '2016', '2015', 'millions', '2017', '2016', '2015', 'Manufacturing', '81.6', '115.6', '81.2', 'Vaccine', 'Discovery', '5.5', '6.1', '6.2', 'Clinical', 'Regulatory', '81.3', '116.2', '75.2', 'Total', 'research', 'development', 'expenses', '168.4', '237.9', '162.6', 'We', 'provide', 'forward-looking', 'estimates', 'costs', 'time', 'complete', 'research', 'programs', 'due', 'many', 'uncertainties', 'associated', 'vaccine', 'development', 'As', 'obtain', 'data', 'preclinical', 'studies', 'clinical', 'trials', 'may', 'elect', 'discontinue', 'delay', 'clinical', 'trials', 'order', 'focus', 'resources', 'promising', 'vaccine', 'candidates', 'Completion', 'clinical', 'trials', 'may', 'take', 'several', 'years', 'length', 'time', 'vary', 'substantially', 'depending', 'upon', 'phase', 'size', 'clinical', 'trial', 'primary', 'secondary', 'endpoints', 'intended', 'use', 'vaccine', 'candidate', 'The', 'cost', 'clinical', 'trials', 'may', 'vary', 'significantly', 'life', 'project', 'result', 'variety', 'factors', 'including', 'number', 'participants', 'participate', 'clinical', 'trials', 'number', 'sites', 'included', 'clinical', 'trials', 'clinical', 'trial', 'locations', 'domestic', 'international', 'time', 'enroll', 'participants', 'duration', 'treatment', 'follow-up', 'safety', 'efficacy', 'profile', 'vaccine', 'candidate', 'cost', 'timing', 'ability', 'secure', 'regulatory', 'approvals', 'As', 'result', 'uncertainties', 'unable', 'determine', 'significant', 'degree', 'certainty', 'duration', 'completion', 'costs', 'research', 'development', 'projects', 'extent', 'generate', 'future', 'cash', 'flows', 'research', 'projects', 'General', 'Administrative', 'Expenses', 'General', 'administrative', 'expenses', 'decreased', '34.5', 'million', '2017', '46.5', 'million', '2016', 'decrease', '12.1', 'million', '26', 'The', 'decrease', 'primarily', 'due', 'lower', 'professional', 'fees', 'including', 'pre-commercialization', 'activities', 'lower', 'employee-related', 'costs', 'compared', '2016', 'At', 'December', '31', '2017', '48', 'employees', 'dedicated', 'general', 'administrative', 'functions', 'versus', '53', 'employees', 'December', '31', '2016', 'For', '2018', 'expect', 'general', 'administrative', 'expenses', 'increase', 'primarily', 'due', 'higher', 'anticipated', 'employee', 'costs', 'professional', 'fees', 'General', 'administrative', 'expenses', 'increased', '46.5', 'million', '2016', '30.8', 'million', '2015', 'increase', '15.7', 'million', '51', 'The', 'increase', 'general', 'administrative', 'expenses', 'primarily', 'due', 'higher', 'employee-related', 'costs', 'driven', 'administrative', 'requirements', 'needed', 'support', 'expanding', 'research', 'development', 'activities', 'professional', 'fees', 'pre-commercialization', 'activities', '51', 'Other', 'Income', 'Expense', '2017', '2016', '2015', 'Change', '2016', '2017', 'Change', '2015', '2016', 'Other', 'Income', 'Expense', 'Investment', 'income', '1,946', '2,143', '660', '197', '1,483', 'Interest', 'expense', '14,072', '12,965', '241', '1,107', '12,724', 'Other', 'income', 'expense', '67', '31', '120', '98', '89', 'Total', 'income', 'expense', 'net', '12,059', '10,853', '299', '1,206', '11,152', 'We', 'total', 'expense', 'net', '12.1', 'million', '2017', 'compared', 'total', 'expense', 'net', '10.9', 'million', '2016', 'increase', '1.2', 'million', 'Our', 'interest', 'expense', 'increased', 'due', 'issuance', '325', 'million', 'aggregate', 'principal', 'amount', 'convertible', 'senior', 'unsecured', 'notes', 'mature', 'February', '1', '2023', 'Notes', 'first', 'quarter', '2016', 'We', 'total', 'expense', 'net', '10.9', 'million', '2016', 'compared', 'total', 'income', 'net', '0.3', 'million', '2015', 'decrease', '11.2', 'million', 'Our', 'investment', 'income', 'increased', '2016', 'compared', '2015', 'due', 'higher', 'cash', 'cash', 'equivalents', 'marketable', 'securities', 'balances', 'Our', 'interest', 'expense', 'increased', 'due', 'issuance', 'Notes', 'first', 'quarter', '2016', 'Net', 'Loss', '2017', '2016', '2015', 'Change', '2016', '2017', 'Change', '2015', '2016', 'Net', 'Loss', 'Net', 'loss', '183,769', '279,966', '156,937', '96,197', '123,029', 'Net', 'loss', 'per', 'share', '0.63', '1.03', '0.60', '0.40', '0.43', 'Weighted', 'average', 'shares', 'outstanding', '292,669', '270,802', '262,248', '21,867', '8,554', 'Net', 'loss', '2017', '183.8', 'million', '0.63', 'per', 'share', 'compared', '280.0', 'million', '1.03', 'per', 'share', '2016', 'decreased', 'net', 'loss', '96.2', 'million', 'The', 'decreased', 'net', 'loss', 'primarily', 'due', 'lower', 'research', 'development', 'spending', 'including', 'decreased', 'costs', 'relating', 'clinical', 'trials', 'development', 'activities', 'RSV', 'F', 'Vaccine', 'lower', 'overall', 'employee-related', 'costs', 'compared', '2016', 'Net', 'loss', '2016', '280.0', 'million', '1.03', 'per', 'share', 'compared', '156.9', 'million', '0.60', 'per', 'share', '2015', 'increased', 'net', 'loss', '123.0', 'million', 'The', 'increased', 'net', 'loss', 'primarily', 'due', 'higher', 'research', 'development', 'spending', 'relating', 'RSV', 'F', 'Vaccine', 'overall', 'higher', 'employee-related', 'costs', 'compared', '2015', 'The', 'increase', 'weighted', 'average', 'shares', 'outstanding', '2017', '2016', 'primarily', 'result', 'sales', 'common', 'stock', '2017', '2015', 'Liquidity', 'Matters', 'Capital', 'Resources', 'Our', 'future', 'capital', 'requirements', 'depend', 'numerous', 'factors', 'including', 'limited', 'commitments', 'progress', 'research', 'development', 'programs', 'progress', 'preclinical', 'clinical', 'testing', 'time', 'costs', 'involved', 'obtaining', 'regulatory', 'approvals', 'costs', 'filing', 'prosecuting', 'defending', 'enforcing', 'patent', 'claims', 'intellectual', 'property', 'rights', 'manufacturing', 'costs', 'We', 'plan', 'continue', 'multiple', 'vaccines', 'product', 'candidates', 'various', 'stages', 'development', 'believe', 'operating', 'expenses', 'capital', 'requirements', 'fluctuate', 'depending', 'upon', 'timing', 'events', 'scope', 'initiation', 'rate', 'progress', 'preclinical', 'studies', 'clinical', 'trials', 'research', 'development', 'activities', 'We', 'primarily', 'funded', 'operations', 'proceeds', 'sale', 'common', 'stock', 'equity', 'offerings', 'issuance', 'convertible', 'debt', 'revenue', 'former', 'contract', 'HHS', 'BARDA', 'current', 'Grant', 'Agreement', 'BMGF', '52', 'As', 'December', '31', '2017', '157.3', 'million', 'cash', 'cash', 'equivalents', 'marketable', 'securities', 'compared', '235.5', 'million', 'December', '31', '2016', 'These', 'amounts', 'consisted', '106.3', 'million', 'cash', 'cash', 'equivalents', '51.0', 'million', 'marketable', 'securities', 'December', '31', '2017', 'compared', '144.4', 'million', 'cash', 'cash', 'equivalents', '91.1', 'million', 'marketable', 'securities', 'December', '31', '2016', 'The', 'following', 'table', 'summarizes', 'cash', 'flows', '2017', '2016', 'thousands', '2017', '2016', 'Change', '2016', '2017', 'Summary', 'Cash', 'Flows', 'Net', 'cash', 'used', 'provided', 'Operating', 'activities', '138,696', '255,467', '116,771', 'Investing', 'activities', '35,968', '28,017', '7,951', 'Financing', 'activities', '64,540', '279,030', '214,490', 'Effect', 'exchange', 'rate', 'cash', 'cash', 'equivalents', '142', '335', '477', 'Net', 'decrease', 'increase', 'cash', 'cash', 'equivalents', '38,046', '51,245', '89,291', 'Cash', 'cash', 'equivalents', 'beginning', 'year', '144,353', '93,108', '51,245', 'Cash', 'cash', 'equivalents', 'end', 'year', '106,307', '144,353', '38,046', 'Net', 'cash', 'used', 'operating', 'activities', 'decreased', '138.7', 'million', '2017', 'compared', '255.5', 'million', '2016', 'The', 'decrease', 'cash', 'usage', 'primarily', 'due', 'decreased', 'costs', 'relating', 'RSV', 'F', 'Vaccine', 'lower', 'overall', 'employee-related', 'costs', 'During', '2017', '2016', 'investing', 'activities', 'consisted', 'primarily', 'purchases', 'maturities', 'marketable', 'securities', 'capital', 'expenditures', 'Capital', 'expenditures', '2017', '2016', '4.2', 'million', '18.2', 'million', 'respectively', 'The', 'decrease', 'capital', 'expenditures', 'primarily', 'due', 'reduced', 'capital', 'requirements', 'based', 'current', 'operating', 'plans', 'In', '2018', 'expect', 'level', 'capital', 'expenditures', 'consistent', '2017', 'spending', 'primarily', 'due', 'timelines', 'extended', 'commercialization', 'RSV', 'F', 'Vaccine', 'Our', 'financing', 'activities', 'consisted', 'primarily', 'sales', 'common', 'stock', 'issuance', 'Notes', 'much', 'lesser', 'extent', 'stock', 'option', 'exercises', 'purchases', 'employee', 'stock', 'purchase', 'plan', 'In', '2017', 'received', 'net', 'proceeds', '63.4', 'million', 'selling', 'shares', 'common', 'stock', 'January', '2017', 'Sales', 'Agreement', 'weighted', 'average', 'sales', 'price', '1.27', 'per', 'share', 'From', 'January', '1', '2018', 'March', '9', '2018', 'sold', 'additional', '19.4', 'million', 'shares', 'commons', 'stock', 'January', '2017', 'December', '2017', 'Sales', 'Agreements', 'resulting', '36.3', 'million', 'net', 'proceeds', 'In', '2016', 'received', 'net', 'proceeds', '276.5', 'million', 'issuance', 'Notes', 'payments', 'capped', 'call', 'transactions', 'see', 'Note', '9', 'consolidated', 'financial', 'statements', 'included', 'herewith', 'In', 'August', '2015', 'amended', 'lease', 'facility', 'located', 'Gaithersburg', 'Maryland', 'increase', 'amount', 'space', 'leased', 'us', 'include', 'entire', 'facility', 'Under', 'terms', 'amended', 'lease', 'landlord', 'provided', 'us', 'tenant', 'improvement', 'allowance', '3.9', 'million', 'fully', 'funded', 'December', '31', '2017', 'In', 'May', '2016', 'entered', 'new', 'lease', 'facility', 'located', 'Gaithersburg', 'Maryland', 'terms', 'lease', 'landlord', 'provided', 'us', 'tenant', 'improvement', 'allowance', '9.6', 'million', '1.2', 'million', 'funded', 'December', '31', '2017', 'In', 'January', '2018', 'new', 'lease', 'terminated', 'paid', 'termination', 'fee', 'landlord', '5.3', 'million', 'first', 'quarter', '2018', 'believe', 'less', 'potential', 'total', 'lease', 'operating', 'expense', 'cash', 'obligations', 'could', 'incurred', 'one', 'year', '53', 'In', '2007', 'entered', 'agreement', 'license', 'certain', 'rights', 'Wyeth', 'The', 'Wyeth', 'license', 'non-exclusive', 'worldwide', 'license', 'family', 'patents', 'patent', 'applications', 'covering', 'VLP', 'technology', 'use', 'human', 'vaccines', 'certain', 'fields', 'expected', 'patent', 'expiration', 'early', '2022', 'The', 'Wyeth', 'license', 'provides', 'us', 'make', 'upfront', 'payment', 'previously', 'made', 'ongoing', 'annual', 'license', 'fees', 'sublicense', 'payments', 'milestone', 'payments', 'certain', 'development', 'commercialization', 'activities', 'royalties', 'product', 'sales', 'Except', 'certain', 'circumstances', 'continuously', 'market', 'multiple', 'products', 'country', 'within', 'vaccine', 'program', 'milestone', 'payments', 'one-time', 'payments', 'applicable', 'related', 'vaccine', 'program', 'At', 'present', 'CPLB', 'recombinant', 'trivalent', 'seasonal', 'VLP', 'influenza', 'vaccine', 'CadiFlu', 'program', 'Wyeth', 'license', 'applies', 'The', 'license', 'may', 'terminated', 'Wyeth', 'cause', 'may', 'terminated', 'us', 'provided', 'ninety', '90', 'days', 'notice', 'absolutely', 'finally', 'ceased', 'activity', 'including', 'affiliate', 'sublicense', 'related', 'manufacturing', 'development', 'marketing', 'sale', 'products', 'covered', 'license', 'In', 'September', '2015', 'amended', 'license', 'agreement', 'Wyeth', 'Among', 'things', 'amendment', 'restructured', '3', 'million', 'milestone', 'payment', 'Milestone', 'owed', 'result', 'CPLB', 'initiation', 'Phase', '3', 'clinical', 'trial', 'CadiFlu', '2014', 'Under', 'amendment', 'milestone', 'payment', 'increased', 'slightly', 'time', 'became', 'due', 'December', '31', '2017', 'The', 'amendment', 'also', 'restructured', 'final', 'milestone', 'payment', 'apply', 'initial', 'seasonal', 'influenza', 'VLP', 'vaccine', 'candidate', 'developed', 'outside', 'India', 'Thus', 'aggregate', 'milestone', 'payments', 'seasonal', 'influenza', 'VLP', 'vaccine', 'candidate', 'developed', 'commercialized', 'increased', '14', 'million', '15', 'million', 'In', 'connection', 'execution', 'amendment', 'agreed', 'pay', 'one-time', 'payment', 'Wyeth', 'The', 'amendment', 'also', 'increased', 'annual', 'license', 'maintenance', 'fees', 'associated', 'VLP', 'vaccine', 'candidates', '0.2', 'million', '0.3', 'million', 'per', 'year', 'Payments', 'agreement', 'Wyeth', 'December', '31', '2017', 'aggregated', '7.6', 'million', 'At', 'December', '31', '2017', 'Milestone', 'recorded', 'accrued', 'expenses', 'consolidated', 'balance', 'sheet', 'expected', 'paid', 'first', 'quarter', '2018', 'The', 'Milestone', 'recorded', 'research', 'development', 'expense', '2014', 'Based', 'recent', 'cash', 'flow', 'forecast', 'believe', 'current', 'capital', 'along', 'anticipated', 'revenue', 'Grant', 'Agreement', 'sufficient', 'fund', 'operating', 'plans', 'minimum', 'twelve', 'months', 'date', 'Annual', 'Report', 'filed', 'Additional', 'capital', 'may', 'required', 'future', 'develop', 'vaccine', 'candidates', 'clinical', 'development', 'manufacturing', 'commercialization', 'We', 'plan', 'meet', 'near', 'term', 'capital', 'requirements', 'primarily', 'cash', 'investments', 'hand', 'combination', 'equity', 'debt', 'financings', 'collaborations', 'strategic', 'alliances', 'marketing', 'distribution', 'licensing', 'arrangements', 'longer', 'term', 'revenue', 'related', 'product', 'sales', 'extent', 'product', 'candidates', 'receive', 'marketing', 'approval', 'commercialized', 'Our', 'ability', 'obtain', 'additional', 'capital', 'near', 'term', 'likely', 'subject', 'various', 'factors', 'including', 'ability', 'perform', 'thus', 'generate', 'revenue', 'Grant', 'Agreement', 'overall', 'business', 'performance', 'market', 'conditions', 'Any', 'capital', 'raised', 'equity', 'offering', 'convertible', 'securities', 'potential', 'substantially', 'dilutive', 'existing', 'stockholders', 'collaborations', 'strategic', 'alliances', 'marketing', 'distribution', 'licensing', 'arrangements', 'may', 'require', 'us', 'give', 'rights', 'product', 'technology', 'less', 'full', 'potential', 'value', 'There', 'assurances', 'new', 'financing', 'available', 'us', 'commercially', 'acceptable', 'terms', 'If', 'unable', 'perform', 'Grant', 'Agreement', 'obtain', 'additional', 'capital', 'assess', 'capital', 'resources', 'may', 'required', 'delay', 'reduce', 'scope', 'eliminate', 'one', 'product', 'research', 'development', 'programs', 'and/or', 'downsize', 'organization', 'including', 'general', 'administrative', 'infrastructure', 'Contractual', 'Obligations', 'The', 'following', 'table', 'summarizes', 'contractual', 'obligations', 'December', '31', '2017', 'thousands', 'Total', 'Less', 'One', 'Year', '1', '3', 'Years', '3', '5', 'Years', 'More', '5', 'Years', 'Contractual', 'Obligations', 'Operating', 'leases', '36,518', '6,695', '12,109', '10,913', '6,801', 'Convertible', 'notes', 'payable', '325,000', '325,000', 'Accrued', 'milestone', 'payment', '4,000', '4,000', 'Total', 'contractual', 'obligations', '365,518', '10,695', '12,109', '10,913', '331,801', 'See', 'Note', '9', 'consolidated', 'financial', 'statements', 'included', 'Annual', 'Report', 'regarding', 'convertible', 'notes', 'payable', 'mature', 'February', '1', '2023', 'Our', 'accrued', 'milestone', 'payment', 'milestone', 'payment', 'incurred', '2014', 'Wyeth', 'agreement', 'expected', 'paid', 'first', 'quarter', '2018', 'see', 'discussion', '54', 'Off-Balance', 'Sheet', 'Arrangements', 'We', 'involved', 'off-balance', 'sheet', 'agreements', 'reasonably', 'likely', 'material', 'future', 'effect', 'financial', 'condition', 'changes', 'financial', 'condition', 'revenue', 'expenses', 'results', 'operations', 'liquidity', 'capital', 'expenditures', 'capital', 'resources', 'Item', '7A.QUANTITATIVE', 'AND', 'QUALITATIVE']